Objective: To conduct a pilot study comparing the effects of quetiapine and placebo for the treatment of depressive episodes in adolescents with bipolar I disorder.
Method: Thirty-two adolescents (ages 12-18 years) with a depressive episode associated with bipolar I disorder were randomized to eight weeks of double-blind treatment with quetiapine, 300-600 mg/day, or placebo. This two-site study was conducted from March 2006 through August 2007. The primary efficacy measure was change in Children's Depression Rating Scale-Revised Version (CDRS-R) scores from baseline to endpoint. Secondary efficacy measures included change in CDRS-R scores over the eight-week study period (PROC MIXED), changes from baseline to endpoint in Hamilton Anxiety Rating Scale (HAM-A), Young Mania Rating Scale (YMRS), and Clinical Global Impression-Bipolar Version Severity (CGI-BP-S) scores, as well as response and remission rates. Safety and tolerability were assessed weekly.
Results: There was no statistically significant treatment group difference in change in CDRS-R scores from baseline to endpoint (p = 0.89, effect size =-0.05, 95% confidence interval: -0.77-0.68), nor in the average rate of change over the eight weeks of the study (p = 0.95). Additionally, there were no statistically significant differences in response (placebo =67% versus quetiapine = 71%) or remission (placebo = 40% versus quetiapine = 35%) rates, or change in HAM-A, YMRS, or CGI-BP-S scores (all p > 0.7) between treatment groups. Dizziness was more commonly reported in the quetiapine (41%) than in the placebo (7%) group (Fisher's exact test, p = 0.04).
Conclusions: The results suggest that quetiapine monotherapy is no more effective than placebo for the treatment of depression in adolescents with bipolar disorder. However, limitations of the study, including the high placebo response rate, may have contributed to our findings and should be considered in the design of future investigations of pharmacological interventions for this population.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1399-5618.2009.00728.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Genetic Analysis of Retinal Cell Types in Neuropsychiatric Disorders.
JAMA Psychiatry
January 2025
Max Planck Institute of Psychiatry, Munich, Germany.
Importance: As an accessible part of the central nervous system, the retina provides a unique window to study pathophysiological mechanisms of brain disorders in humans. Imaging and electrophysiological studies have revealed retinal alterations across several neuropsychiatric and neurological disorders, but it remains largely unclear which specific cell types and biological mechanisms are involved.
Objective: To determine whether specific retinal cell types are affected by genomic risk for neuropsychiatric and neurological disorders and to explore the mechanisms through which genomic risk converges in these cell types.
Medication non-adherence and its predictors among patients with bipolar disorder in Northwest Ethiopia.
Sci Rep
January 2025
Department of Pharmacy, College of Health Science, Debre Markos University, Debre Markos, Ethiopia.
While pharmacotherapy is the primary approach for treating patients with bipolar disorder, non-adherence is the most common barrier preventing these patients from achieving optimal medication effectiveness. This study aimed to assess medication non-adherence and its predictors among patients with bipolar disorder in Northwest Ethiopia. A hospital-based cross-sectional study was conducted among 404 patients with bipolar disorder in Northwest Ethiopia from January to March 2024.
View Article and Find Full Text PDFDevelopment and Predictors of Bipolar Disorder in Children and Adolescents with Depressive Disorders A Systematic Review, Meta-analysis and Meta-regression.
Eur Psychiatry
January 2025
National Institute for Health Research, Maudsley Biomedical Research Centre, South London and Maudsley NHS Foundation Trust, London, UK.
Magnitude and correlates of internalised stigma among outpatient psychiatric service users in southeast central Ethiopia.
BMC Psychiatry
January 2025
Department of Epidemiology and Biostatistics, Institute of Health, School of Public Health, Jimma University, Jimma, Ethiopia.
Background: Stigma is recognised as one of the most significant barriers to treatment for people with mental health conditions. However, limited studies are available in low-resource settings.
Objectives: To assess the magnitude of internalised stigma and associated factors among people with mental health conditions attending tertiary outpatient psychiatric services in Ethiopia.
Long-Acting Injectable Antipsychotics in Adolescents with Bipolar Disorder.
J Child Adolesc Psychopharmacol
January 2025
Director of Co-Founder and Founder of Schizophrenia Society, University of Cincinnati, Cincinnati, Ohio, USA.
Bipolar disorder often begins in adolescence or early adulthood, characterized by recurrent manic episodes that can lead to neurodegenerative brain changes and functional decline. While several oral second-generation antipsychotics are Food and Drug Administration (FDA)-approved for mania, adherence to maintenance treatment is frequently poor due to factors such as anosognosia, cognitive dysfunction, impulsivity, side effects aversion, and substance use. Long-acting injectable (LAI) antipsychotics, approved for adults with bipolar mania or schizoaffective disorder (bipolar type), offer a potential solution for adolescents with similar conditions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!